A Tolerability and Pharmacokinetics Study of SHR6390 in Advanced Melanoma Patients
Status:
Unknown status
Trial end date:
2017-04-01
Target enrollment:
Participant gender:
Summary
SHR6390 is a small molecular,oral potent, selective CDK4/6 inhibitor. The purpose of this
study is to investigate the safety/tolerability and the pharmacokinetic profile of SHR6390 in
Chinese advanced melanoma patients by using a "3+3" dose escalation.Preliminary efficacy will
be also investigated in this study.